Adesis is a US-based CDMO specializing in peptides and oligonucleotide  to support our customers’ development and clinical pipelines. With a team of 100+ chemists at our Delaware facility, we execute both solid-phase and solution-phase synthesis, delivering linear and cyclic targets using a range of modern coupling strategies. Our scientists tailor resin/solvent systems, activators, and protecting-group schemes to the sequence and scale, enabling efficient route scouting, robust process development, and reliable scale-up.

Downstream, we apply a range of purification and desalting approaches, supported by fit-for-purpose analytics to confirm identity, purity, and sequence integrity. Whether your priority is a quick feasibility readout, scale-up readiness, or troubleshooting a difficult sequence, our team brings hands-on experience across peptides and oligos to keep programs moving.

Our capabilities include:
• Peptides: Linear and cyclic peptides for therapeutic research. Examples: oxytocin (linear), cyclosporine A (cyclic), RGD peptide (integrin-binding).
• Oligonucleotides: For antisense therapies and biotech applications. Examples: 20-mer DNA oligonucleotide (antisense DNA), siRNA strands (e.g., ALN-TTR02).
• Peptide-Oligonucleotide Conjugates (POCs): Conjugates for advanced therapeutics. Examples: GalNAc-conjugated siRNA (inclisiran conjugate), peptide-DNA conjugate (CPP-DNA for cell delivery).